Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting CK2 for cancer therapy.

Kashif A Ahmad1, Guixia Wang, Joel Slaton

  • 1Cellular and Molecular Biochemistry Research Laboratory, Minneapolis Veterans Affairs Medical Center, Chaska, Minnesota 55417, USA. ahmedk@umn.edu

Anti-Cancer Drugs
|October 14, 2005
PubMed
Summary

Antisense CK2alpha oligodeoxynucleotide (ODN) effectively induces cancer cell apoptosis and tumor resolution. Normal cells show resistance, suggesting a therapeutic window for this novel cancer therapy targeting dysregulated protein kinase CK2.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transformer-based models for predicting cardiovascular risk in Chinese adults: development and validation.

European heart journal·2026
Same author

Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial.

Diabetology & metabolic syndrome·2026
Same author

Microwave digestion-ICP-MS coupled with molecular docking: unraveling elemental distribution and its correlation with glucose and fructose accumulation in 25 strawberry cultivars.

Food chemistry·2026
Same author

Lifetime cumulative effect of reproductive factors, "Life's essential 8" health status and risk of chronic kidney disease: a nationwide prospective cohort study.

BMC public health·2026
Same author

Age-stratified associations of glycemia, blood pressure, and cholesterol with mortality in diabetes: A prospective cohort study.

BMC medicine·2026
Same author

Age-specific effects of hemoglobin A1c, blood pressure, and cholesterol levels on incident cardiovascular diseases among adults with diabetes in China: a 10-year prospective cohort study.

Life metabolism·2026

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • Protein kinase CK2 is a ubiquitous enzyme involved in cell growth, proliferation, and apoptosis suppression.
  • CK2 is dysregulated in all examined cancers and exhibits dynamic intracellular shuttling, predominantly in the nucleus of cancer cells.
  • Downregulating CK2 induces apoptosis, suggesting its potential as a cancer therapeutic target.

Purpose of the Study:

  • To investigate the efficacy of antisense CK2alpha oligodeoxynucleotide (ODN) in inducing apoptosis in cancer cells and xenograft models.
  • To assess the therapeutic window of antisense CK2alpha ODN by evaluating its effect on normal versus cancer cells.
  • To explore novel delivery methods for enhancing targeted cancer therapy.

Main Methods:

  • Utilized antisense CK2alpha oligodeoxynucleotide (ODN) in cancer cell cultures and xenograft models (prostate cancer, head and neck squamous cell carcinoma).

Related Experiment Videos

  • Assessed dose- and time-dependent effects of ODN on tumor cell death and tumor resolution.
  • Investigated the differential sensitivity of normal and cancer cells to antisense ODN treatment.
  • Explored targeted delivery using sub-50-nm tenascin nanocapsules.

    • Main Results:

    • Antisense CK2alpha ODN demonstrated potent induction of apoptosis in cancer cells and complete resolution of xenograft tumors at optimal concentrations.
    • Normal and benign cells exhibited relative resistance to antisense CK2alpha ODN treatment, indicating a potential therapeutic window.
    • Novel nanocapsule delivery systems showed promise for targeted cancer cell delivery.

    Conclusions:

    • Antisense CK2alpha ODN is a potent inducer of apoptosis in cancer cells, with significant tumor-resolving capabilities.
    • The differential sensitivity between cancer and normal cells suggests a favorable therapeutic window for antisense CK2alpha ODN therapy.
    • Targeted delivery approaches, such as nanocapsules, enhance the specificity and potential efficacy of this cancer therapeutic strategy.